NCT03737994 2026-03-18
Targeted Treatment for ALK Positive Patients Who Have Previously Been Treated for Non-squamous Non-small Cell Lung Cancer
National Cancer Institute (NCI)
Phase 2 Active not recruiting
Clinical Trials
9 trialsNCT06678555 2026-02-05
A Study to Learn About Lorlatinib in Patients With Non-Small Cell Lung Cancer (NSCLC) Which Has Spread Out.
Pfizer
Active not recruiting
NCT05740943 2026-01-20
Induction Lorlatinib in Stage III Non-small Cell Lung Cancer
Guangdong Provincial People's Hospital
Phase 2 Active not recruiting
NCT05297890 2025-12-23
A Study of Lorlatinib in Subjects With ROS1-Positive Non-Small Cell Lung Cancer
CStone Pharmaceuticals
Phase 2 Active not recruiting
NCT05144997 2025-12-17
Lorlatinib Continuation Study
Pfizer
Phase 4 Active not recruiting
NCT03052608 2025-11-25
A Study Of Lorlatinib Versus Crizotinib In First Line Treatment Of Patients With ALK-Positive NSCLC
Pfizer
Phase 3 Active not recruiting
NCT04621188 2025-09-24
Lorlatinib After Failure of First-line TKI in Patients With Advanced ROS1-positive NSCLC (ALBATROS)
Intergroupe Francophone de Cancerologie Thoracique
Phase 2 Active not recruiting
NCT04127110 2024-11-05
ALKALINE
European Organisation for Research and Treatment of Cancer - EORTC
Phase 2 Active not recruiting
NCT06410040 2024-05-10
A Retrospective Study of the Efficacy and Safety of Lolatinib in ALK+ NSCLC Patients With Brain or Meningeal Metastasis
Sichuan Cancer Hospital and Research Institute
Active not recruiting